EU-Africa PerMed:
Outcome of the 1st Stakeholder Workshop
The CSA EU-Africa PerMed started successfully in its
second project year on February 01, with the first
Stakeholder Workshop that took place virtually on
February 09-10, 2022. The event was hosted by the
NACOSTI, the Kenya National Commission for Science
Technology and Innovation and brought together around
150 stakeholders of 41 different countries.
On the first day, EU-Africa PerMed and ICPerMed were
presented and the European Commission’s vision about
collaboration between Africa and Europe in personalised
medicine (PM) outlined. African speakers provided an
overview of PM across the different African regions and
discussed with the participants about challenges
and opportunities around PM implementation in
Africa.
The second day focused on identifying and
prioritising PM needs in Africa, with a key
note presentation of the South African PM programme and
discussions in five breakout groups. The workshop was
closed with discussions around the potential and
advantages of collaboration in the field of Personalised
Medicine between Africa and Europe.
The workshop report will be published soon, while the
presentations and recordings are already available here.
Upcoming event: 1st EU-Africa PerMed Webinar:
"Oncology and Personalised Medicine: bi-regional
perspective from Africa and Europe"; May 17, 2022, 12:00
CET, 14:00 EAT, 13:00 N/SAT; Registration
Follow EU-Africa PerMed: Contact
form; Twitter @EU_AfricaPerMed and LinkedIn @
EU-AFRICA PerMed Project; Website; Join
EU-Africa PerMeds public
discussions.
Sino-EU PerMed: 1st International Stakeholder
Workshop
On February 17, 2022 Fondazione Toscana Life
Sciences, partner of the European funded project SINO-EU
PerMed, hosted the first international stakeholder
workshop in Florence and online. Over 80 stakeholders,
with interdisciplinary background joined from over 10
countries and 3 continents to discuss the Sino-EU
cooperation in Personalised Medicine.
Launched in 2020, the first phase of the project
focused on mapping the recent collaborations between
Europe and China in Personalised Medicine-related
science and technology. The event was built on the
results of these activities and aimed at discussing the
main barriers and needs identified to foster
collaboration among the two regions. Selected experts in
the field gathered to discuss and co-create a joint
policy paper which might pave the way to an increased
level of collaboration. This policy paper will be shared
with policy makers as well as scientific and industrial
communities.
Further information on the event and the
presentations can be found on the Sino-EU
PerMed webpage.
SAPHIRe: Final conference “Personalised
Medicine in European Regions - A Roadmap to the
Future of Medicine”
The SAPHIRe consortium is coming to an end in 2022
and the final conference is coming up!
SAPHIRe, which stands for Securing the Adoption of
Personalised Health in Regions, is a project initiated
to support the development and implementation of
personalised medicine in European regions, including in
remote and sparsely populated regions, and to establish
and support networking between regions.
On April 25-26, 2022, SAPHIRe will
hold its final conference entitled “Personalised
Medicine in European Regions—A Roadmap to the Future of
Medicine” in the Flemish Parliament in Brussels
(IJzerenkruisstraat 99). The event will provide insight
and inspiration into how regions contribute to the
development and implementation of personalised medicine.
After two years of online meetings and teleworking, this
event is an opportunity to meet each other in person
again. The event will be COVID-safe and follow the
latest recommendations.
The event will feature speakers from all over the
quadruple helix (university, industry, policy,
citizens). Lessons learned during the project will be
highlighted and the event will offer a chance to engage
in interregional networking.
Registration Please register here
Agenda
The conference is free of charge, but you should pay
your own travel and accommodation.
HEcoPerMed: New publication by HEcoPerMed on
the Net Benefit of Personalized Medicine in Value in
Health
HEcoPerMed recently published an article
about the Net Benefit of Personalized Medicine in Value
in Health. The authors explore why the analysis
of cost-effectiveness for PM delivers very heterogeneous
results, and how the most promising areas for further
investment could be found.
Previous reviews on the cost-effectiveness of
personalised medicine (PM) have found that most PM
interventions increase costs and health benefits. They
have also found large heterogeneity in outcomes. We
expand on previous research by focusing on incremental
net monetary benefit (ΔNMB) as opposed to incremental
cost-effectiveness ratios, which allows for easy ranking
of the interventions and for assessing the magnitude of
their benefit. We explore the heterogeneity in outcomes
using regression analysis.
PM interventions were found to have modest health
benefits compared with non-PM. Nevertheless, its costs
tend to result in 0 to negative ΔNMB on average. Gene
therapies were found to have larger health benefits than
other PM interventions. Nevertheless, they were also
associated with higher costs and significantly lower
ΔNMB, though this finding was sensitive to (small) data
changes and hence uncertain. PM interventions for
neoplasms had lower Δcosts and larger ΔNMB than PM
interventions for other conditions, yet average ΔNMB in
the 'neoplasm' group was still negative. Pricing
policies may be needed to reduce the costs of gene
therapies and other interventions with negative ΔNMB.
Beyond the difference between gene therapies and
other PM interventions, no statistically significant
factors could be identified to explain the large
heterogeneity in cost-effectiveness outcomes. It appears
that the term “personalised medicine” may be too general
given that it conceals sizable differences in the net
benefit of different PM interventions. A more precise
division into subcategories of PM may be needed to
uncover the most promising areas for further investment.
Link
to the article The latest HEcoPerMed Newsletter
can be found here.
|